ClinicalTrials.gg
CompletedNCT01247324Updated Mar 4, 2024Results posted

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

A Phase 3 interventional study of Interferon beta-1a and Ocrelizumab-matching placebo in Relapsing Multiple Sclerosis, sponsored by Hoffmann-La Roche. Completed at 142 sites in 32 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
821
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
5th of 27
821 · median 170
Started
2011
with 1 other
Phase 3
13 of 27
2 open now
Registered
1st of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 13 in phase 3, and was the 1st registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis. Participants will be randomized to receive either ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week; or interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks). Planned duration of double-blind treatment is 96 weeks. Participants who complete the 96-week double-blind treatment will have an option to enter a single-group, active-treatment, open-label extension period, providing they fulfill the eligibility criteria.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)
  • At least 2 documented clinical attacks within the last 2 years prior to screening or one clinical attack in the years prior to screening (but not within 30 days prior to screening)
  • Neurologic stability for greater than or equal to (>=) 30 days prior to both screening and baseline
  • Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive

Exclusion criteria

Exclusion Criteria:

  • Primary progressive multiple sclerosis
  • Disease duration of more than 10 years in participants with EDSS less than or equal to (\<=) 2.0 at screening
  • for MRI
  • Known presence of other neurological disorders which may mimic multiple sclerosis
  • Pregnancy or lactation
  • Requirement for chronic treatment with systemic or during the course of the study
  • History of or currently active primary or secondary immunodeficiency
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Active infection, or history of or known presence of recurrent or chronic infection (e.g., or C, [HIV], syphilis, tuberculosis)
  • History of progressive multifocal leukoencephalopathy
  • Contraindications to or intolerance of oral or iv corticosteroids
  • Contraindications to Rebif or incompatibility with Rebif use
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
821 participants (actual)

Study arms

  • Active comparator
    Interferon beta-1a 44 mcg SC

    Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).

    Drug: Interferon beta-1a · Drug: Ocrelizumab-matching placebo

  • Experimental
    Ocrelizumab

    Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.

    Drug: Ocrelizumab · Drug: Interferon beta-1a-matching placebo

Interventions

  • Also known as: Rebif

  • DrugOcrelizumab-matching placebo
  • Also known as: RO4964913

  • DrugInterferon beta-1a-matching placebo
06

What researchers measure

Primary outcomes

  1. Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks

    ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.

    Time frame: Week 96

Secondary outcomes

  1. Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period

    Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

    Time frame: Week 108

  2. Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment

    The total number of T1 gadolinium-enhancing lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

    Time frame: Baseline up to Week 96

  3. Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment

    The total number of new and/or enlarging T2 lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

    Time frame: Baseline up to Week 96

  4. Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks

    Disability improvement was assessed only for the subgroup of participants with a baseline EDSS score of \>= 2.0. It was defined as a reduction in EDSS score of: A) \>=1.0 from the baseline EDSS score when the baseline score was \>=2 and \<=5.5 B) \>= 0.5 when the baseline EDSS score \> 5.5. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined.

    Time frame: Week 96

  5. Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period

    Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

    Time frame: Week 108

  6. Number of T1 Hypointense Lesions During the Double-Blind Treatment

    The total number of new T1-Hypo-Intense Lesions (Chronic Black Holes) for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and 96.

    Time frame: Baseline up to Week 96

  7. Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96

    MSFC score consists of: A) Timed 25-Foot walk; B) 9-Hole Peg Test (9-HPT); and C) Paced Auditory Serial Addition Test (PASAT-3 version). The MSFCS is based on the concept that scores for these three dimensions (arm, leg, and cognitive function) are combined to create a single score (the MSFC) that can be used to detect change over time in a group of participants with MS. Since the three primary measures differ in what they actually measure, a common composite score for the three different measures i.e., Z- score was selected for the purpose. MSFC Score = {Z arm, average + Z leg, average + Z cognitive} / 3.0. The results from each of these three tests are transformed into Z-scores and averaged to yield a composite score for each participant at each time point. A score of +1 indicates that, on average, an individual scored 1 standard deviation (SD) better than the reference population and a score of -1 indicates that an individual scored 1 SD worse than the reference population.

    Time frame: Baseline, Week 96

  8. Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96

    Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. Therefore, brain volume at Week 24 was calculated as the brain volume at the baseline visit multiplied by 1 + (\[percentage change in brain volume from baseline visit to Week 24\]/100). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Baseline EDSS (\< 4.0 vs. \>= 4.0) + Week + Treatment + Treatment\*Week (repeated values over Week) + Brain Volume at Week 24\*Week.

    Time frame: From Week 24 up to Week 96

  9. Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t- scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

    Time frame: Baseline, Week 96

  10. Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96

    NEDA was defined only for participants with a baseline EDSS score \>=2.0. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Participants who completed the 96- week treatment period were considered as having evidence of disease activity if at least one protocol- defined relapse (PDR), a confirmed disability progression (CDP) event or at least one MRI scan showing MRI activity (defined as Gd-enhancing T1 lesions, or new or enlarging T2 lesions) was reported during the 96-week treatment period, otherwise the participant was considered as having NEDA.

    Time frame: Week 96

  11. Number of Participants With Adverse Events (AEs)

    AEs included infusion related reactions (IRRs) and serious MS relapses, but excluded non-serious MS relapses. Serious Adverse Events (SAEs) included serious MS relapses and serious IRRs.

    Time frame: Baseline up to 588 weeks

  12. Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC)

    AUC represents total drug exposure for one dosing interval after the 4th dose.

    Time frame: Pre-infusion at Weeks 1, 24, 48, 72; and 30 minutes post-infusion at Week 72; at any time during Weeks 84 and 96

  13. Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab

    Number of participants positive for anti-drug antibodies (ADAs) to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.

    Time frame: Baseline up to week 96

07

Results

Posted Jul 18, 2017

Participant flow

1051 participants were screened for entry into study. 821 participants were entered into double-blind treatment period. Participants who completed the 96-week double-blind treatment had option to enter a single group, active treatment open label extension, providing they fulfilled the eligibility criteria and at study completion date, all participants are provided opportunity to rollover and continue treatment and/or safety follow-up under new extension protocol MN43964 (NCT05269004).

Participant flow — Overall Study
MilestoneInterferon Beta-1a 44 mcg SCOcrelizumab
Started411410
Entered open-label extension326352
Completed226239
Not completed185171
Withdrew: Death610
Withdrew: Physician decision23
Withdrew: Non-compliance with study drug30
Withdrew: Lack of efficacy2414
Withdrew: Non-compliance32
Withdrew: Pregnancy510
Withdrew: Protocol violation11
Withdrew: Reason not specified4232
Withdrew: Consent withdrawn by participant4156
Withdrew: Adverse event4935
Withdrew: Lost to follow-up36
Withdrew: Study terminated by sponsor41
Withdrew: Missing21

Outcome measures

PrimaryAnnualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks

ARR was protocol-defined and calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of exposure to that treatment.

Time frame:
Week 96
Reported as:
Number · relapses/participant year of treatment
Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks
relapses/participant year of treatmentInterferon Beta-1a 44 mcg SCOcrelizumab
Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks0.292 (0.235 to 0.361)0.156 (0.122 to 0.200)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = <0.0001 · Rate ratio: 0.536 · 95% CI 0.4 to 0.719Rate ratio was calculated as Ocrelizumab ARR/Interferon beta-1a 44 mcg SC ARR.
SecondaryTime to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period

Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

Time frame:
Week 108
Reported as:
Median · weeks
Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period
weeksInterferon Beta-1a 44 mcg SCOcrelizumab
Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment PeriodNA (0 to 103)NA (0 to 108)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Log Rank · p = = 0.0139 · Hazard ratio (hr): 0.57 · 95% CI 0.37 to 0.90
SecondaryNumber of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment

The total number of T1 gadolinium-enhancing lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

Time frame:
Baseline up to Week 96
Reported as:
Number · lesions
Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment
lesionsInterferon Beta-1a 44 mcg SCOcrelizumab
Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment33721
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = < 0.0001 · Adjusted rate ratio: 0.058 · 95% CI 0.032 to 0.104Adjusted by baseline T1 Gd lesion (present or not), baseline EDSS (\<4.0 vs. \>=4.0) and geographical region (US vs. rest-of-world). Adjusted rate ratio was calculated as Ocrelizumab adjusted rate/Interferon beta-1a 44 mcg SC adjusted rate.
SecondaryNumber of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment

The total number of new and/or enlarging T2 lesions for all participants in the treatment group was calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96.

Time frame:
Baseline up to Week 96
Reported as:
Number · lesions
Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment
lesionsInterferon Beta-1a 44 mcg SCOcrelizumab
Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment1916430
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = < 0.0001 · Adjusted rate ratio: 0.229 · 95% CI 0.174 to 0.300Adjusted by baseline T2 lesion (present or not), baseline EDSS (\<4.0 vs. \>=4.0) and geographical region (US vs. rest-of-world). Adjusted rate ratio was calculated as Ocrelizumab adjusted rate/Interferon beta-1a 44 mcg SC adjusted rate.
SecondaryPercentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks

Disability improvement was assessed only for the subgroup of participants with a baseline EDSS score of \>= 2.0. It was defined as a reduction in EDSS score of: A) \>=1.0 from the baseline EDSS score when the baseline score was \>=2 and \<=5.5 B) \>= 0.5 when the baseline EDSS score \> 5.5. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks
percentage of participantsInterferon Beta-1a 44 mcg SCOcrelizumab
Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks12.42 (8.94 to 16.64)20.00 (15.69 to 24.89)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · CMH Chi-Squared test (stratified) · p = = 0.0106 · Relative risk (stratified): 1.61 · 95% CI 1.11 to 2.33CMH (Cochran-Mantel-Haenszel) Chi-Squared test Stratified by Geographical Region (US vs. Rest of World) and Baseline EDSS (\<4.0 vs. \>=4.0)
SecondaryTime to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period

Disability progression was defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) \>=1.0 point from the baseline EDSS score when the baseline score was less than or equal to (\<=) 5.5 B) \>=0.5 point from the baseline EDSS score when the baseline score was \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). This outcome measure was considered confirmatory only when results of both studies WA21092 and WA21093 were combined. Disability progression was considered confirmed when the increase in the EDSS was confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. Participants who had initial disability progression with no confirmatory EDSS assessment and who were on treatment at time of clinical cut-off date were censored at the date of their last EDSS assessment.

Time frame:
Week 108
Reported as:
Median · weeks
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period
weeksInterferon Beta-1a 44 mcg SCOcrelizumab
Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment PeriodNA (0 to 103)NA (0 to 108)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Log Rank · p = = 0.0278 · Hazard ratio (hr): 0.57 · 95% CI 0.34 to 0.95
SecondaryNumber of T1 Hypointense Lesions During the Double-Blind Treatment

The total number of new T1-Hypo-Intense Lesions (Chronic Black Holes) for all participants in the treatment group was calculated as the sum of the individual number of new lesions at Weeks 24, 48, and 96.

Time frame:
Baseline up to Week 96
Reported as:
Number · lesions
Number of T1 Hypointense Lesions During the Double-Blind Treatment
lesionsInterferon Beta-1a 44 mcg SCOcrelizumab
Number of T1 Hypointense Lesions During the Double-Blind Treatment1307564
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · Negative Binomial Model · p = < 0.0001 · Adjusted rate ratio: 0.428 · 95% CI 0.328 to 0.557Adjusted by baseline T1-hypointense lesion count, baseline EDSS (\<4.0 vs. \>=4.0) and geographical region (US vs. rest-of-world). Adjusted rate ratio was calculated as Ocrelizumab adjusted rate/Interferon beta-1a 44 mcg SC adjusted rate.
SecondaryChange From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96

MSFC score consists of: A) Timed 25-Foot walk; B) 9-Hole Peg Test (9-HPT); and C) Paced Auditory Serial Addition Test (PASAT-3 version). The MSFCS is based on the concept that scores for these three dimensions (arm, leg, and cognitive function) are combined to create a single score (the MSFC) that can be used to detect change over time in a group of participants with MS. Since the three primary measures differ in what they actually measure, a common composite score for the three different measures i.e., Z- score was selected for the purpose. MSFC Score = {Z arm, average + Z leg, average + Z cognitive} / 3.0. The results from each of these three tests are transformed into Z-scores and averaged to yield a composite score for each participant at each time point. A score of +1 indicates that, on average, an individual scored 1 standard deviation (SD) better than the reference population and a score of -1 indicates that an individual scored 1 SD worse than the reference population.

Time frame:
Baseline, Week 96
Reported as:
Mean · Z-score
Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96
Z-scoreInterferon Beta-1a 44 mcg SCOcrelizumab
Unadjusted Baseline mean0.028 ± 0.034-0.012 ± 0.040
Adjusted Week 96 mean0.174 ± 0.0310.213 ± 0.031
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · mixed-effect model of repeated measures · p = = 0.3261 · Difference in adjusted means: 0.039 · 95% CI -0.039 to 0.116Difference in adjusted means was calculated as Ocrelizumab adjusted mean at Week 96/ Interferon beta-1a 44 mcg SC adjusted mean at Week 96.
SecondaryPercent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96

Brain volume was recorded as an absolute "normalized" value at the baseline visit then recorded at subsequent visits as a percentage change relative to the absolute value at the baseline visit. Therefore, brain volume at Week 24 was calculated as the brain volume at the baseline visit multiplied by 1 + (\[percentage change in brain volume from baseline visit to Week 24\]/100). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM) using unstructured covariance matrix: Percentage Change = Brain Volume at Week 24 + Geographical Region (US vs. ROW) + Baseline EDSS (\< 4.0 vs. \>= 4.0) + Week + Treatment + Treatment\*Week (repeated values over Week) + Brain Volume at Week 24\*Week.

Time frame:
From Week 24 up to Week 96
Reported as:
Mean · percent change
Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96
percent changeInterferon Beta-1a 44 mcg SCOcrelizumab
Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96-0.741 ± 0.046-0.572 ± 0.044
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · mixed-effect model of repeated measures · p = = 0.0042 · Difference in adjusted means: 0.168 · 95% CI 0.053 to 0.283Difference in the rate of brain volume loss: 22.8%. Difference in adjusted means was calculated as Ocrelizumab adjusted mean at Week 96/ Interferon beta-1a 44 mcg SC adjusted mean at Week 96.
SecondaryChange From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t- scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

Time frame:
Baseline, Week 96
Reported as:
Mean · t-score
Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96
t-scoreInterferon Beta-1a 44 mcg SCOcrelizumab
Unadjusted Baseline mean45.399 ± 0.52945.065 ± 0.507
Adjusted mean change at week 96-0.657 ± 0.4750.036 ± 0.456
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · mixed-effect model of repeated measures · p = = 0.2193 · Difference in adjusted means: 0.693 · 95% CI -0.414 to 1.800Difference in adjusted means was calculated as Ocrelizumab adjusted mean at Week 96/ Interferon beta-1a 44 mcg SC adjusted mean at Week 96.
SecondaryPercentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96

NEDA was defined only for participants with a baseline EDSS score \>=2.0. The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Participants who completed the 96- week treatment period were considered as having evidence of disease activity if at least one protocol- defined relapse (PDR), a confirmed disability progression (CDP) event or at least one MRI scan showing MRI activity (defined as Gd-enhancing T1 lesions, or new or enlarging T2 lesions) was reported during the 96-week treatment period, otherwise the participant was considered as having NEDA.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96
percentage of participantsInterferon Beta-1a 44 mcg SCOcrelizumab
Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 9627.1 (22.1 to 32.6)47.4 (41.5 to 53.3)
Statistical analysis
  • Interferon Beta-1a 44 mcg SC vs Ocrelizumab · CMH Chi-Squared test (stratified) · p = < 0.0001 · Relative risk (stratified): 1.74 · 95% CI 1.39 to 2.17Analyzed using CMH test, stratified by Geographical Region (US vs. rest-of-world) and baseline EDSS (\<4.0 vs. \>=4.0).
SecondaryNumber of Participants With Adverse Events (AEs)

AEs included infusion related reactions (IRRs) and serious MS relapses, but excluded non-serious MS relapses. Serious Adverse Events (SAEs) included serious MS relapses and serious IRRs.

Time frame:
Baseline up to 588 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsInterferon Beta-1a + Placebo (Double Blind Period)Ocrelizumab + Placebo (Double Blind Period)Interferon Beta-1a + Placebo (Open Label Extension)Ocrelizumab + Placebo (Open Label Extension)
Number of Participants With Adverse Events (AEs)331327302319
SecondaryExposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC)

AUC represents total drug exposure for one dosing interval after the 4th dose.

Time frame:
Pre-infusion at Weeks 1, 24, 48, 72; and 30 minutes post-infusion at Week 72; at any time during Weeks 84 and 96
Reported as:
Mean · micrograms per milliliter*day
Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC)
micrograms per milliliter*dayOcrelizumab
Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC)3513 ± 955
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab

Number of participants positive for anti-drug antibodies (ADAs) to ocrelizumab is the number of post- baseline evaluable participants determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.

Time frame:
Baseline up to week 96
Reported as:
Number · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab
ParticipantsInterferon Beta-1a 44 mcg SCOcrelizumab
Positive sample at baseline21
Positive for ADA post-baseline21

Adverse events

Collected over Baseline to approximately 588 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Interferon Beta -1a + Placebo (Double Blind Period)1/409 (0.2%)32/409 (7.8%)257/409 (62.8%)
Ocrelizumab + Placebo (Double Blind Period)0/408 (0%)28/408 (6.9%)241/408 (59.1%)
Interferon Beta-1a + Placebo (Open Label Extension)6/326 (1.8%)109/326 (33.4%)285/326 (87.4%)
Ocrelizumab + Placebo (Open Label Extension)11/352 (3.1%)116/352 (33%)286/352 (81.3%)
Most frequent serious events
Showing 10 of 254
Most frequent serious events
EventInterferon Beta -1a + Placebo (Double Blind Period)Ocrelizumab + Placebo (Double Blind Period)Interferon Beta-1a + Placebo (Open Label Extension)Ocrelizumab + Placebo (Open Label Extension)
COVID-19 PNEUMONIAInfections and infestations0/4090/40817/32620/352
PNEUMONIAInfections and infestations0/4090/40811/3266/352
COVID-19Infections and infestations0/4090/4086/3268/352
PYREXIAGeneral disorders0/4090/4081/3265/352
MULTIPLE SCLEROSIS RELAPSENervous system disorders3/4090/4083/3265/352
URINARY TRACT INFECTIONInfections and infestations1/4090/4084/3261/352
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/4090/4084/3261/352
ANGINA PECTORISCardiac disorders0/4090/4080/3264/352
MYOCARDIAL INFARCTIONCardiac disorders0/4090/4080/3264/352
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/4090/4083/3260/352
Most frequent other events
Showing 10 of 38
Most frequent other events
EventInterferon Beta -1a + Placebo (Double Blind Period)Ocrelizumab + Placebo (Double Blind Period)Interferon Beta-1a + Placebo (Open Label Extension)Ocrelizumab + Placebo (Open Label Extension)
INFUSION RELATED REACTIONInjury, poisoning and procedural complications31/409126/40883/32671/352
COVID-19Infections and infestations0/4090/40896/32696/352
URINARY TRACT INFECTIONInfections and infestations56/40952/40880/326101/352
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations35/40959/40889/32690/352
MULTIPLE SCLEROSIS RELAPSENervous system disorders0/4090/40882/32684/352
NASOPHARYNGITISInfections and infestations40/40942/40868/32673/352
INFLUENZA LIKE ILLNESSGeneral disorders85/40914/4080/3260/352
INJECTION SITE ERYTHEMAGeneral disorders73/4090/4080/3260/352
BRONCHITISInfections and infestations0/4090/40846/32651/352
ARTHRALGIAMusculoskeletal and connective tissue disorders30/40927/40846/32629/352

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants in the study.

Age, Continuous
Age, Continuous(years)Interferon Beta-1a 44 mcg SCOcrelizumabTotal
Mean36.9 ± 9.337.1 ± 9.337.0 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Interferon Beta-1a 44 mcg SCOcrelizumabTotal
Female272270542
Male139140279
08

Study locations

142 sites
  • 21st Century Neurology
    Phoenix, Arizona 85004, United States
  • Mercy Medical Group
    Carmichael, California 95608, United States
  • Scripps Clinic
    La Jolla, California 92037, United States
  • MS Center of California
    Laguna Hills, California 92653, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Neuro-Therapeutics Inc.
    Pasadena, California 91105, United States
  • University of California at San Francisco
    San Francisco, California 94115, United States
  • Health First Physicians Inc.
    Melbourne, Florida 32901, United States
  • Mercy Research Institute
    Miami, Florida 33133, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33609, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Shepherd Center Inc.
    Atlanta, Georgia 30309, United States
  • Emory University; Department of Neurology
    Atlanta, Georgia 30322, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Northwestern University; Dept. of Neurology
    Chicago, Illinois 60611, United States
  • Consultants in Neurology Ltd
    Northbrook, Illinois 60062, United States
  • American Health Network Institute, LLC
    Avon, Indiana 46123, United States
  • Massachusetts General Hospital.
    Boston, Massachusetts 02114, United States
  • Michigan Neurology Associates P.C.
    Clinton Township, Michigan 48035, United States
  • Michigan Institute for Neurological Disorders
    Farmington Hills, Michigan 48334, United States
  • The Minneapolis Clinic of Neurology
    Golden Valley, Minnesota 55422, United States
  • Washington University; Wash Uni. Sch. Of Med
    Saint Louis, Missouri 63110, United States
  • The MS Center for Innovations In Care
    Saint Louis, Missouri 63131, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-0600, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • The MS Center; Advance Neurology and Pain
    Advance, North Carolina 27006, United States
  • Atrium Health Neurosciences Institute ? Charlotte
    Charlotte, North Carolina 28204, United States
  • OnSite Clinical Solutions LLC
    Charlotte, North Carolina 28277, United States
  • Neurology Associates PA
    Hickory, North Carolina 28602, United States
  • University Neurology Inc.
    Cincinnati, Ohio 45219, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43212, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Providence Neurological Specialties
    Portland, Oregon 97225, United States
  • Albert Einstein Medical Center; Depatment of Neurosensory sciences
    Philadelphia, Pennsylvania 19141, United States
  • Magee-Woman's Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Uni of Texas Health Science Center At Houston
    Houston, Texas 77030, United States
  • Bhupesh Dihenia M.D. P.A.
    Lubbock, Texas 79410, United States
  • Uni of Vermont Medical Center;
    Burlington, Vermont 05405, United States
  • Multicare Research Institute; Multicare Neuroscience Center of Washington
    Tacoma, Washington 98405, United States
  • Instituto centenario
    Buenos Aires, C1204AAD, Argentina
  • Hospital Español
    Ciudad Autonoma Bs As, C1209AAB, Argentina
  • Fundacion Rosarina de Neurorehabilitacion
    Rosario, S2000BZL, Argentina
  • Royal North Shore Hospital; Department of Neurology
    St Leonards, New South Wales 2065, Australia
  • Barmherzige Brueder Konventspital
    Linz, 4040, Austria
  • AZ Sint Jan
    Brugge, 8000, Belgium
  • Cliniques Universitaires Saint-Luc; Neurology
    Bruxelles, 1200, Belgium
  • AZ Delta (Campus Rumbeke)
    Roeselare, 8800, Belgium
  • Hospital das Clinicas - UFG;Reumatologia
    Goiania, GO 74653-050, Brazil
  • IMV Pesquisa Neurológica
    Porto Alegre, RS 90110-000, Brazil
  • Clinica Neurologica; Neurocirurgica de Joinville
    Joinville, SC 89202-190, Brazil
  • MHAT Avis Medica; Neurology Department
    Pleven, 5800, Bulgaria
  • First MHAT; Clinic of Neurology
    Sofia, 1000, Bulgaria
  • MHATNP Sv.Naum EAD; Clinic in neurology diseases for movement disorders
    Sofia, 1113, Bulgaria
  • ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine
    Sofia, 1407, Bulgaria
  • Military Medical Academy; Neurology
    Sofia, 1606, Bulgaria
  • Hospital Carlos Van Buren
    Valparaiso, 2340000, Chile
  • Fakultni nemocnice u sv. Anny; Neurologicka klinika
    Brno, 656 91, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Nemocnice Jihlava; NEU-Neurologicke oddeleni
    Jihlava, 58633, Czechia
  • Krajska Nemocnice Pardubice Neurologicka Klinika
    Pardubice, 532 03, Czechia
  • VFN Praha Poliklinika Rs Centrum - Budova A
    Prague, 12808, Czechia
  • Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni
    Teplice, 415 29, Czechia
  • West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • FinnMedi Oy
    Tampere, 33520, Finland
  • Groupe Hospitalier Pellegrin
    Bordeaux, 33000, France
  • CHU Hopital Gabriel Montpied; Service de Neurologie
    Clermont Ferrand, 63003, France
  • Hopital Central; Neurologie
    Nancy, 54035, France
  • CHU de Nîmes Hopital Caremeau; Service de Neurologie
    Nimes, 30900, France
  • Hopital Hautepierre - CHU Strasbourg; Service de Neurologie
    Strasbourg, 67098, France
  • Charité Universitaetsmedizin Berlin, Campus Charité Mitte
    Berlin, 10117, Germany
  • Universitätsklinikum "Carl Gustav Carus"; MS Center Dresden
    Dresden, 01307, Germany
  • Asklepiosklinik Barmbek; Abteilung Neurologie
    Hamburg, 22291, Germany
  • Diakoniekrankenhaus Henriettenstiftung gGMBH; Klinik für Neurologie und klinische Neurophysiologie
    Hannover, 30171, Germany
  • Universitaetsklinikum Mainz - PS; Klinik und Poliklinik fuer Neurologie
    Mainz, 55131, Germany
  • Praxis Dr. med. Mathias Niedhammer, Facharzt für Neurologie
    Oldenburg, 26122, Germany
  • Neurozentrum Prien Elisabeth Hans-Thümmler Stefan Braune
    Prien, 83209, Germany
  • Universitätsklinikum Rostock, Zentrum für Nervenheilkunde; Klinik und Poliklinik für Neurologie
    Rostock, 18147, Germany
  • Universitätsklinikum Tübingen, Zentrum für Neurologie
    Tübingen, 72076, Germany
  • Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz
    Westerstede, 26655, Germany
  • Semmelweis Egyetem AOK; Neurologiai Klinika
    Budapest, 1083, Hungary
  • Fovarosi Onkormanyzat Jahn Ferenc Del-Pesti
    Budapest, 1204, Hungary
  • Szent Borbala Korhaz; Neurology
    Tatabánya, 2800, Hungary
  • Chaim Sheba Medical Center; Neurology Department
    Ramat-Gan, 5262000, Israel
  • Azienda Ospedaliera Sant'Andrea
    Roma, Lazio 00189, Italy
  • Irccs Ospedale San Raffaele
    Milano, Lombardia 20132, Italy
  • Azienda Socio Sanitaria Territoriale della Valle Olona (pres
    Gallarate, Valle D?Aosta 21013, Italy
  • Azienda Ospedaliera di Padova; Clinica Neurologica
    Padova, Veneto 35128, Italy
  • Maritime Medicine Centre of Latvia Hospital of Vecmilgravis Department of Neurology
    Riga, 1015, Latvia
  • P. Stradins Clinical University Hospital; Neurology
    Riga, LV-1002, Latvia
  • Kaunas Medical University Hospital
    Kaunas, 50009, Lithuania
  • Klaipeda University Hospital Public Institution
    Klaipeda, 92288, Lithuania
  • Vilnius University Hospital Santariskiu Clinic
    Vilnius, 08661, Lithuania
  • Grupo Médico Camino S.C.
    Ciudad de México, Mexico CITY (federal District) 03600, Mexico
  • Hospital Universitario Dr Jose Eleuterio Gonzalez; Universidad Autónoma de Nuevo León
    Monterrey, Nuevo LEON 64460, Mexico
  • St. Antonius Ziekenhuis Nieuwegein
    Nieuwegein, 3435 CM, Netherlands
  • Policlinico Especializado en Neurologia
    Callao, 04, Peru
  • Clinica Anglo Americana
    Lima, 18, Peru
  • Hospital Nacional Dos de Mayo
    Lima, Peru

Showing the first 100 of 142 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Arnold DL, Sprenger T, Bar-Or A, Wolinsky JS, Kappos L, Kolind S, Bonati U, Magon S, van Beek J, Koendgen H, Bortolami O, Bernasconi C, Gaetano L, Traboulsee A. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Mult Scler. 2022 Oct;28(12):1927-1936. doi: 10.1177/13524585221097561. Epub 2022 Jun 7. PubMed 35672926 ↗
  • Krishnan AP, Song Z, Clayton D, Gaetano L, Jia X, de Crespigny A, Bengtsson T, Carano RAD. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials. Radiology. 2022 Mar;302(3):662-673. doi: 10.1148/radiol.211528. Epub 2021 Dec 14. PubMed 34904871 ↗
  • Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, Wolinsky JS. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. Eur J Neurol. 2022 Apr;29(4):1238-1242. doi: 10.1111/ene.14823. Epub 2021 May 5. PubMed 33724637 ↗
  • Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020 Sep 29;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376. Epub 2020 Jul 20. PubMed 32690791 ↗
  • Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. PubMed 32511687 ↗
  • Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. PubMed 28002679 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Apr 2015, 43 months.

Results were first posted in Jul 2017, 2 years 3 months after primary completion. A results delay was requested in Oct 2016.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 43 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2010
First posted
Nov 24, 2010
StartActual
Aug 31, 2011
Primary completionActual
Apr 2, 2015
CompletionActual
Dec 31, 2022
Results delay requested
Oct 10, 2016
Results first posted
Jul 18, 2017
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01247324
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 24, 2010
Start date
Aug 31, 2011
Primary completion
Apr 2, 2015
Completion
Dec 31, 2022
Results posted
Jul 18, 2017
Last update
Mar 4, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion